• Contact
• Dr Thomas Borcholte
• Chief Business Officer
• Tel.: +49 (0)89 - 41 31 38 - 0
• E-Mail: licensing@wilex.com

Cooperations

ENGLISH DEUTSCH

WILEX collaborates and has license agreements with a number of leading academic and clinical institutions as well as pharmaceutical companies in Europe and North America. The Company considers these relationships to be important to its ability to gain access to and exploit possible new developments within its business focus.

Strategic Alliance

• UCB Pharma S.A., Brussels, Belgium, 2009: UCB and WILEX to enter into strategic alliance to develop UCB’s preclinical oncology portfolio. (Press Release)
• Bayer Corporation, Tarrytown, NY, USA, 2001: Licensing agreement on MN/CA IX antigen of the RENCAREX^® antibody. (Press Release)
• Centocor Inc., Malvern, USA/University of Leiden, Netherlands, 1999: Licensing of G250/RENCAREX^® antibody. (Press release)

Scientific Alliances

• Ludwig Institute for Cancer Research, New York, USA, 2001: Clinical Phase I and II trials with WX-G250 antibody and 124Iodine-G250 in the US. (Press release)
• Fox Chase Cancer Center, Philadelphia, USA, 2003: Collaboration to conduct clinical Phase I and II trials with MESUPRON^® in combination with capecitabine. The studies are supported with a USD 5.0 million grant from the U.S. Department of Defense Breast Cancer Research Program. (Press release)
• Department of Urology of the David Geffen School of Medicine at UCLA, University of California, Los Angeles, USA: Collaboration with a research group of Prof. Arie Belldegrun to examine the pre-clinical efficacy of the WX-G250 (RENCAREX^®) antibody in mouse models
• Slovak Academy of Sciences, Bratislava, Slovakia: Collaboration with a research group of Prof. Pastorek to examine the CAIX antigen and the mode of action of the WX-G250 (RENCAREX^®) antibody in different models
• Erasmus Medical Center, Rotterdam, Netherlands: Research collaboration on pre-clinical tests of WILEX’s drug candidates

Licence agreements are an important part of the Company’s commercialisation strategy. You will find details of existing partnerships or options for further cooperations here.

 Print This Page |  Email This Page